S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% BITCOIN 64,403.62 -0.61%
Next Bullish Trade
Sign in
IMUX

Immunic, Inc. NCM · IMUX

$15.16 +0.13 (+0.86%)
Neutral · +0.49σ

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · IMUX

Momentum reads · latest daily bar
Last
$15.16
+0.13 (+0.86%)
Mkt cap
$207M
Healthcare
RSI(14)
59.0
neutral
Stochastic %K
56.5
neutral
MFI(14)
57.4
neutral
ADX(14)
23.8
building

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $-0.0B $-0.0B $-0.0B
2025-12-31 $-0.0B $-0.0B $-0.0B
2025-09-30 $-0.0B $-0.0B $-0.0B
2025-06-30 $-0.0B $-0.0B $-0.0B
2025-03-31 $-0.0B $-0.0B $-0.0B
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare IMUX vs peers

Line IMUX up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing IMUX no peers yet — add up to 4 below

Add tickers to compare with IMUX

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-13 -1.08 -0.96 -12.8% -2.3%
2026-02-26 -0.70 -1.11 +37.0% +7.6%
2025-11-13 -1.30 -1.77 +26.4% +9.3%
2025-08-07 -2.00 -1.58 -26.3% -3.3%
2025-05-15 -2.50 -2.40 -4.2% -3.5%
2025-03-31 -2.50 -2.38 -4.9% -2.3%
2024-11-07 -2.40 -2.18 -9.9% +0.0%
2024-08-08 -2.10 -2.33 +9.7% -0.8%
2024-05-08 -3.00 -2.65 -13.2% -2.4%
2024-02-22 -4.80 -5.40 +11.1% +0.0%
2023-11-14 -5.10 -5.07 -0.5% +1.0%
2023-08-03 -5.40 -5.12 -5.4% -5.6%
2023-05-11 -5.80 -4.80 -20.8% -4.4%
2023-02-23 -5.88 -7.42 +20.8% -4.1%
2022-11-03 -6.90 -6.95 +0.7% -3.8%
2022-08-04 -7.20 -7.30 +1.4% +11.3%
2022-05-10 -7.40 -7.57 +2.3% -4.7%
2022-02-24 -8.06 -7.58 -6.3% -0.3%
2021-11-04 -7.60 -7.52 -1.1% -0.5%
2021-08-06 -8.20 -6.67 -23.0% +6.2%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
IMUX $0B -4.3 -0.2 1.4 -20.04%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0%
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 40.53%

HolderShares% out
Marshall Wace LLP 952,966 7.00%
Aberdeen Group plc 824,394 6.05%
BVF Inc. 765,297 5.62%
Avidity Partners Management, LP 669,941 4.92%
Vanguard Capital Management LLC 513,832 3.77%
Soleus Capital Management, L.P. 450,000 3.30%
Laurion Capital Management, LP 388,216 2.85%
Millennium Management Llc 377,992 2.77%
Morgan Stanley 328,854 2.41%
Nantahala Capital Management, LLC 250,649 1.84%

Insider activity · 90d

7 buys / 0 sells · ratio 7.0 · Finnhub

  • Skerjanec Simona BUY 25,370
  • Rudick Richard Alan BUY 25,370
  • Neermann Joerg BUY 25,370
  • Congleton Jon BUY 25,370
  • PHILLIPS BARCLAY A BUY 25,370
  • Lundgren Erik BUY 1,000,000
  • Panzara Michael A. BUY 300,000

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$19.0
Mean
$44.66667
High
$85.0
Analysts
9
Recommendation distribution · period 2026-07-01
7
8
1
Revision trend (2026-04-01 → 2026-07-01): net 14 → 15 +1 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
8-K 2026-07-14 Material event (8-K) view ·
4 2026-07-07 Insider transaction (Form 4) view ·
4 2026-07-07 Insider transaction (Form 4) view ·
4 2026-07-07 Insider transaction (Form 4) view ·
4 2026-07-07 Insider transaction (Form 4) view ·
4 2026-07-07 Insider transaction (Form 4) view ·
8-K 2026-07-06 Material event (8-K) view ·
4 2026-06-29 Insider transaction (Form 4) view ·
4 2026-06-29 Insider transaction (Form 4) view ·
4 2026-06-29 Insider transaction (Form 4) view ·
4 2026-06-29 Insider transaction (Form 4) view ·
4 2026-06-29 Insider transaction (Form 4) view ·
4 2026-06-29 Insider transaction (Form 4) view ·
4 2026-06-29 Insider transaction (Form 4) view ·
4 2026-06-29 FORM 4 view ·
4 2026-06-29 Insider transaction (Form 4) view ·
4 2026-06-29 Insider transaction (Form 4) view ·
8-K 2026-06-29 Material event (8-K) view ·
4 2026-06-01 Insider transaction (Form 4) view ·
DEF 14A 2026-05-29 Proxy statement view ·
8-K 2026-05-28 Material event (8-K) view ·
8-K 2026-05-27 Material event (8-K) view ·
8-K 2026-05-19 Material event (8-K) view ·
8-K 2026-05-13 Material event (8-K) view ·
10-Q 2026-05-13 10-Q view ·
4 2026-04-29 Insider transaction (Form 4) view ·
8-K 2026-04-28 Material event (8-K) view ·
8-K 2026-04-23 Material event (8-K) view ·
8-K 2026-04-14 Material event (8-K) view ·
8-K 2026-04-10 Material event (8-K) view ·
8-K 2026-04-01 Material event (8-K) view ·
8-K 2026-03-31 Material event (8-K) view ·
DEF 14A 2026-03-02 Proxy statement view ·
10-K 2026-02-26 10-K view ·
8-K 2026-02-26 Material event (8-K) view ·
8-K 2026-02-13 Material event (8-K) view ·
8-K 2026-01-06 Material event (8-K) view ·
8-K 2026-01-05 Material event (8-K) view ·
8-K 2025-11-13 Material event (8-K) view ·
10-Q 2025-11-13 10-Q view ·
8-K 2025-09-25 Material event (8-K) view ·
10-Q 2025-08-07 10-Q view ·
8-K 2025-08-07 Material event (8-K) view ·
4 2025-07-18 FORM 4 view ·
4 2025-07-18 Insider transaction (Form 4) view ·
4 2025-07-18 Insider transaction (Form 4) view ·
4 2025-07-18 Insider transaction (Form 4) view ·
4 2025-07-18 Insider transaction (Form 4) view ·
8-K 2025-07-11 Material event (8-K) view ·
8-K 2025-06-27 Material event (8-K) view ·
4 2025-06-16 Insider transaction (Form 4) view ·
4 2025-06-09 Insider transaction (Form 4) view ·
4 2025-06-09 Insider transaction (Form 4) view ·
4 2025-06-09 Insider transaction (Form 4) view ·
4 2025-06-09 Insider transaction (Form 4) view ·
4 2025-06-09 Insider transaction (Form 4) view ·
4 2025-06-09 Insider transaction (Form 4) view ·
4 2025-06-09 FORM 4 view ·
4 2025-06-09 Insider transaction (Form 4) view ·
4 2025-06-09 Insider transaction (Form 4) view ·

About IMUX

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Options picks · IMUX

ITM + OTM ideas from the latest scan

Loading…

Congress trades · IMUX

STOCK Act disclosures

Loading…

SEC filings & insiders · IMUX

EDGAR · live

Loading…

Holders · IMUX

Institutions & insider activity

Loading…